Chase Knickerbocker

Boobalan Pachaiyappan

Brandon Folkes

Raghuram Selvaraju

Ram Selvaraju

Roy Buchanan

- PolyPid Ltd. announced the **successful completion of a routine Good Manufacturing Practice (GMP) inspection** by the Israeli Ministry of Health, marking its **fourth consecutive successful inspection** of its manufacturing facility.  **[1611842_0001213900-25-087942_ea025753001ex99-1_polypid.htm:0]** 
- This milestone confirms the facility's readiness for **commercial production in the European market** under the EU-Israel ACAA framework and serves as crucial preparation for a **U.S. FDA facility inspection**.  **[1611842_0001213900-25-087942_ea025753001ex99-1_polypid.htm:0]** 
- The company anticipates submitting a **New Drug Application (NDA) for D-PLEX100 in early 2026**, following positive Phase 3 SHIELD II trial results that demonstrated a **58% relative risk reduction in surgical site infections**.  **[1611842_0001213900-25-087942_ea025753001ex99-1_polypid.htm:0]** **[1611842_0001213900-25-087942_ea025753001ex99-1_polypid.htm:1]**

PolyPid (PYPD)